RxDoctor Payments Data

Deval Gadhvi, MD

Internal Medicine · Jersey City, NJNPI 1518119700

Payments from drug & device makers

$5,727in general payments, 2019–2025

Across 147 payments — averaging $38.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • Biohaven Pharmaceuticals, Inc.$1K
  • AstraZeneca$1K
  • AbbVie$311
  • Medtronic$306
  • Pfizer$206
  • plus $822 from 11 others

What the payments were for

  • Consulting fees$1,20021%
  • Food & beverage$4,50479%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,727 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$23,778
Medicare patients
52
Services billed
220

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$29,617
OzempicSemaglutide14$15,556
JanuviaSitagliptin Phosphate12$10,247
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,021
Albuterol Sulfate HfaAlbuterol Sulfate44$1,530
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$1,460
Telmisartan23$1,230
Nebivolol Hcl21$881
Metformin Hcl72$651
Atorvastatin Calcium68$612
Montelukast Sodium41$547
Levothyroxine Sodium50$508
Rosuvastatin Calcium48$489
Simvastatin45$424
Metoprolol Succinate30$422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$1,692$29,61733 claims
Novo NordiskOzempic$85$15,55614 claims
AstraZenecaBreztri Aerosphere$1,176$7,02111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Jersey City

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →